Big Sioux Wealth Management’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-337
Closed -$1.31K – 318
2026
Q2
$1.31K Hold
337
– – ﹤0.01% 353
2026
Q1
$1.29K Hold
337
– – ﹤0.01% 349
2025
Q4
$1.26K Buy
+337
New +$1.11K ﹤0.01% 345

Other funds holding SABS

Big Sioux Wealth Management's SABS Position: Q3 2026 in Review

Big Sioux Wealth Management sold out of SAB Biotherapeutics (SABS) in Q3 2026, closing a stake of 337 shares — an estimated $1.31K sold.

Big Sioux Wealth Management first reported a position in SABS in Q4 2025 and held it in 3 quarters. The position peaked at $1.31K in Q2 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Big Sioux Wealth Management reported no remaining SAB Biotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Big Sioux Wealth Management sold 337 SAB Biotherapeutics shares in Q3 2026, an estimated $1.31K.
  • Big Sioux Wealth Management first reported a position in SAB Biotherapeutics in Q4 2025 and held it in 3 quarters.
  • Big Sioux Wealth Management's SAB Biotherapeutics position peaked at $1.31K in Q2 2026.
  • 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Big Sioux Wealth Management's 13F filing for Q3 2026, filed 19 Nov 2026.